




INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6 : C07C 259/06		A1	(11) International Publication Number: WO 97/43249 (43) International Publication Date: 20 November 1997 (20.11.97)
(21) International Application Number: PCT/EP97/02433			(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ARIPO patent (GH, KE, LS, MW, SD, SZ, UG), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).
(22) International Filing Date: 6 May 1997 (06.05.97)			
(30) Priority Data: 9609794.4 10 May 1996 (10.05.96) GB			
(71) Applicant (for all designated States except US): SMITHKLINE BEECHAM PLC [GB/GB]; New Horizons Court, Brentford, Middlesex TW8 9EP (GB).			
(72) Inventors; and			
(75) Inventors/Applicants (for US only): BAILEY, Stuart [GB/GB]; SmithKline Beecham Pharmaceuticals, Great Bürgh, Yew Tree Bottom Road, Epsom, Surrey KT18 5XQ (GB). BUCKLE, Derek, Richard [GB/GB]; SmithKline Beecham Pharmaceuticals, Great Bürgh, Yew Tree Bottom Road, Epsom, Surrey KT18 5XQ (GB). FALLER, Andrew [GB/GB]; SmithKline Beecham Pharmaceuticals, New Frontiers Science Park South, Harlow, Essex CM19 5AW (GB). SMITH, David, Glynn [GB/GB]; SmithKline Beecham Pharmaceuticals, New Frontiers Science Park South, Harlow, Essex CM19 5AW (GB).			
(74) Agent: WEST, Vivien; SmithKline Beecham plc, New Horizons Court, Brentford, Middlesex TW8 9EP (GB).			

(54) Title: INHIBITORS OF THE PRODUCTION OF s-CD23 AND THE SECRETION OF TNF

(57) Abstract

Compounds of formula (I) wherein: R is hydroxy, hydrogen, alkyl, alkenyl, alkynyl or aryl; R¹ is arylmethyl or heterocyclmethyl; R² is alkyl, alkenyl, aryl, cycloalkyl or cycloalkenyl; and R³ is hydrogen, alkyl, alkenyl, alkynyl or aryl; with the proviso that: if R¹ is phenylmethyl or naphthylmethyl, wherein the phenyl or naphthyl group is unsubstituted or substituted by up to five substituents selected from the group consisting of halogen, (C₁₋₆)alkyl, aryl(C₁₋₆)alkyl, (C₁₋₆)alkoxy, (C₁₋₆)alkoxy(C₁₋₆)alkyl, halo(C₁₋₆)alkyl, hydroxy, nitro, amino, mono- and di-N-(C₁₋₆)alkylamino, acylamino, acyloxy, carboxy, carboxy salts, carboxy esters, carbamoyl, mono- and di-N-(C₁₋₆)alkylcarbamoyl, (C₁₋₆)alkoxycarbonyl, aryloxycarbonyl, ureido, guanidino, sulphonylamino, aminosulphonyl, (C₁₋₆)alkylthio, (C₁₋₆)alkyl sulphinyl (C₁₋₆)alkylsulphonyl, heterocycl, heterocycl (C₁₋₆)alkyl, and a (C₃₋₅)alkylene chain linking two adjacent ring carbon atoms to form a carbocyclic ring; then R is hydroxy; are useful in the treatment of disorders mediated by s-CD23.



FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LJ	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

INHIBITORS OF THE PRODUCTION OF s-CD23 AND THE SECRETION OF TNF

This invention relates to novel inhibitors of the formation of soluble human CD23 and their use in the treatment of conditions associated with excess 5 production of soluble CD23 (s-CD23) such as autoimmune disease and allergy. The compounds of the invention are also inhibitors of the release of tumour necrosis factor (TNF).

CD23 (the low affinity IgE receptor Fc ϵ RII, Blast 2), is a 45 kDa type II integral protein expressed on the surface of a variety of mature cells, including B 10 and T lymphocytes, macrophages, natural killer cells, Langerhans cells, monocytes and platelets (Delespesse *et al*, *Adv Immunol*, **49** [1991] 149-191). There is also a CD23-like molecule on eosinophils (Granette *et al*, *J Immunol*, **143** [1989] 3580-3588). CD23 has been implicated in the regulation of the immune response (Delespesse *et al*, *Immunol Rev*, **125** [1992] 77-97). Human 15 CD23 exists as two differentially regulated isoforms, a and b, which differ only in the amino acids at the intracellular N-terminus (Yokota *et al*, *Cell*, **55** [1988] 611-618). In man the constitutive a isoform is found only on B-lymphocytes, whereas type b, inducible by IL4, is found on all cells capable of expressing CD23.

Intact, cell bound CD23 (i-CD23) is known to undergo cleavage from the 20 cell surface leading to the formation of a number of well-defined soluble fragments (s-CD23), which are produced as a result of a complex sequence of proteolytic events, the mechanism of which is still poorly understood (Bourget *et al* *J Biol Chem*, **269** [1994] 6927-6930). Although not yet proven, it is postulated that the major soluble fragments (Mr 37, 33, 29 and 25 kDa) of these proteolytic 25 events, all of which retain the C-terminal lectin domain common to i-CD23, occur sequentially via initial formation of the 37 kDa fragment (Letellier *et al*, *J Exp Med*, **172** [1990] 693-700). An alternative intracellular cleavage pathway leads to a stable 16 kDa fragment differing in the C-terminal domain from i-CD23 (Grenier-Brosette *et al*, *Eur J Immunol*, **22** [1992] 1573-1577).

30 Several activities have been ascribed to membrane bound i-CD23 in humans, all of which have been shown to play a role in IgE regulation. Particular

cytotoxicity, c) B cell homing to germinal centres of lymph nodes and spleen, and d) downregulation of IgE synthesis (Delespesse *et al*, *Adv Immunol*, **49**, [1991] 149-191). The three higher molecular weight soluble CD23 fragments (Mr 37, 33 and 29 kDa) have multifunctional cytokine properties which appear to play a

5 major role in IgE production. Thus, the excessive formation of s-CD23 has been implicated in the overproduction of IgE, the hallmark of allergic diseases such as extrinsic asthma, rhinitis, allergic conjunctivitis, eczema, atopic dermatitis and anaphylaxis (Sutton and Gould, *Nature*, **366**, [1993] 421-428). Other biological activities attributed to s-CD23 include the stimulation of B cell growth and the

10 induction of the release of mediators from monocytes. Thus, elevated levels of s-CD23 have been observed in the serum of patients having B-chronic lymphocytic leukaemia (Sarfati *et al*, *Blood*, **71** [1988] 94-98) and in the synovial fluids of patients with rheumatoid arthritis (Chomarat *et al*, *Arthritis and Rheumatism*, **36** [1993] 234-242). That there is a role for CD23 in inflammation is suggested by a

15 number of sources. First, sCD23 has been reported to bind to extracellular receptors which when activated are involved in cell-mediated events of inflammation. Thus, sCD23 is reported to directly activate monocyte TNF, IL-1, and IL-6 release (Armant *et al*, vol 180, *J.Exp. Med.*, 1005-1011 (1994)). CD23 has been reported to interact with the B2-integrin adhesion molecules, CD11b and

20 CD11c on monocyte/macrophage (S. Lecoanet-Henchoz *et al*, *Immunity*, vol 3; 119-125 (1995)) which trigger NO₂⁻, hydrogen peroxide and cytokine (IL-1, IL-6, and TNF) release. Finally, IL-4 or IFN induce the expression of CD23 and its release as sCD23 by human monocytes. Ligation of the membrane bound CD23 receptor with IgE/anti-IgE immune complexes or anti CD23 mAb activates cAMP

25 and IL-6 production and thromboxane B2 formation, demonstrating a receptor-mediated role of CD23 in inflammation.

Because of these various properties of CD23, compounds which inhibit the formation of s-CD23 should have twofold actions of a) enhancing negative feedback inhibition of IgE synthesis by maintaining levels of i-CD23 on the

30 surface of B cells, and b) inhibiting the immunostimulatory cytokine activities of higher molecular weight soluble fragments (Mr 37, 33 and 29 kDa) of s-CD23. In addition, inhibition of CD23 cleavage should mitigate sCD23-induced


monocyte activation and mediator formation, thereby reducing the inflammatory response.

TNF α is a pro-inflammatory cytokine which is released from stimulated cells by specific cleavage of a 76-amino acid signal sequence in the inactive 5 precursor to generate the mature form. The cleavage of TNF α has been reported to be carried out by a metalloprotease (Gearing, A.J.H. et al, (1994) *Nature* 370, 555-557; McGeehan, G.M. et al, (1994) *Nature* 370, 558-561; Mohler, K.M. et al, (1994) *Nature* 370, 218-220). Compounds reported to inhibit the cleavage of TNF α by the TNF processing enzyme can be broadly described as matrix 10 metalloprotease inhibitors, particularly of the hydroxamic acid class.

TNF α is induced in a variety of cell types in response to bacteria, endotoxin, various viruses and parasites, so that one physiological function ascribed to TNF α is a contribution to the inflammatory response to acute infection by bacteria, parasites, etc (Dinarello, C.A. (1992) *Immunol. Rev.* 4, 133-15 145). Overproduction of TNF α has been implicated in disease states such as rheumatoid arthritis, septic shock, Crohn's disease and cachexia (Dinarello, 1992). Inhibition of processing of TNF α to the mature, active form would therefore be beneficial in the treatment of these inflammatory disorders. TNF α may also contribute to the destruction of tissue in autoimmune disease although it is not a 20 initiating factor in these diseases. Confirming the importance of TNF α in rheumatoid arthritis, TNF α antibodies have been shown to reduce the severity of disease in short term studies in rheumatoid arthritis models (Elliott, M.J., et al (1993) *Arthritis. Rheum.* 12, 1681-1690; Elliott et al (1994) *Lancet* 344, 1125-1127).

25 International Patent Application No. WO 96/02240 (Smithkline Beecham plc) discloses that compounds which inhibit the action of matrix metalloproteases (eg collagenase, stromelysin and gelatinase) are effective inhibitors of the release of human soluble CD23 transfected into mammalian cell culture systems.

UK Patent Application No. 9601041.8 (Smithkline Beecham plc) 30 discloses that certain compounds of formula (I) are effective inhibitors of the release of human soluble CD23 transfected into mammalian cell culture systems:



According to the present invention, there is provided a compound of formula (I) above, wherein:

- 5 R is hydroxy, hydrogen, alkyl, alkenyl, alkynyl or aryl;
- R¹ is arylmethyl or heterocyclmethyl;
- R² is alkyl, alkenyl, aryl, cycloalkyl or cycloalkenyl; and
- R³ is hydrogen, alkyl, alkenyl, alkynyl or aryl;
- with the proviso that;
- 10 if R¹ is phenylmethyl or naphthylmethyl, wherein the phenyl or naphthyl group is unsubstituted or substituted by up to five substituents selected from the group consisting of halogen, (C₁₋₆)alkyl, aryl(C₁₋₆)alkyl, (C₁₋₆)alkoxy, (C₁₋₆)alkoxy(C₁₋₆)alkyl, halo(C₁₋₆)alkyl, hydroxy, nitro, amino, mono- and di-N-(C₁₋₆)alkylamino, acylamino, acyloxy, carboxy, carboxy salts, carboxy esters,
- 15 carbamoyl, mono- and di-N-(C₁₋₆)alkylcarbamoyl, (C₁₋₆)alkoxycarbonyl, aryloxycarbonyl, ureido, guanidino, sulphonylamino, aminosulphonyl, (C₁₋₆)alkylthio, (C₁₋₆)alkyl sulphanyl (C₁₋₆)alkylsulphonyl, heterocycl, heterocycl (C₁₋₆)alkyl, and a (C₃₋₅)alkylene chain linking two adjacent ring carbon atoms to form a carbocyclic ring;
- 20 then R is hydroxy.

Alkyl, alkenyl and alkynyl groups referred to herein include straight and branched groups containing up to six carbon atoms and are optionally substituted by one or more groups selected from the group consisting of aryl, heterocycl, (C₁₋₆)alkylthio, (C₁₋₆)alkoxy, aryl(C₁₋₆)alkoxy, aryl(C₁₋₆)alkylthio, amino, mono- or di-(C₁₋₆)alkylamino, cycloalkyl, cycloalkenyl, carboxy and esters thereof, hydroxy, and halogen.

Cycloalkyl and cycloalkenyl groups referred to herein include groups having between three and eight ring carbon atoms and are optionally substituted as described hereinabove for alkyl, alkenyl and alkynyl groups.

When used herein, the term "aryl" means single and fused rings suitably containing from 4 to 7, preferably 5 or 6, ring atoms in each ring, which rings, may each be unsubstituted or substituted by, for example, up to three substituents. A fused ring system may include aliphatic rings and need include only one aromatic ring.

5 Suitable aryl groups include phenyl and naphthyl such as 1-naphthyl or 2-naphthyl.

10 Suitably any aryl group, including phenyl and naphthyl, may be optionally substituted by up to five, preferably up to three substituents. Suitable substituents include halogen, (C₁₋₆)alkyl, aryl, aryl(C₁₋₆)alkyl, (C₁₋₆)alkoxy, (C₁₋₆)alkoxy(C₁₋₆)alkyl, halo(C₁₋₆)alkyl, aryl(C₁₋₆)alkoxy, hydroxy, nitro, cyano, azido, amino, mono- and di-N-(C₁₋₆)alkylamino, acylamino, arylcarbonylamino, acyloxy, carboxy, carboxy salts, carboxy esters, carbamoyl, mono- and di-N-(C₁₋₆)alkylcarbamoyl, (C₁₋₆)alkoxycarbonyl, aryloxycarbonyl, ureido, guanidino, sulphonylamino, aminosulphonyl, (C₁₋₆)alkylthio, (C₁₋₆)alkyl sulphinyl, (C₁₋₆)alkylsulphonyl, heterocyclyl and heterocyclyl (C₁₋₆)alkyl. In 15 addition, two adjacent ring carbon atoms may be linked by a (C₃₋₅)alkylene chain, to form a carbocyclic ring.

20 When used herein the terms "heterocyclyl" and "heterocyclic" suitably include, unless otherwise defined, aromatic and non-aromatic, single and fused, rings suitably containing up to four heteroatoms in each ring, each of which is selected from oxygen, nitrogen and sulphur, which rings, may be unsubstituted or substituted by, for example, up to three substituents. Each heterocyclic ring 25 suitably has from 4 to 7, preferably 5 or 6, ring atoms. A fused heterocyclic ring system may include carbocyclic rings and need include only one heterocyclic ring.

30 Preferably a substituent for a heterocyclyl group is selected from halogen, (C₁₋₆)alkyl, aryl(C₁₋₆)alkyl, (C₁₋₆)alkoxy, (C₁₋₆)alkoxy(C₁₋₆)alkyl, halo(C₁₋₆)alkyl, hydroxy, amino, mono- and di-N-(C₁₋₆)alkyl-amino, acylamino, carboxy salts, carboxy esters, carbamoyl, mono- and di-N-(C₁₋₆)alkylcarbamoyl, aryloxycarbonyl, (C₁₋₆)alkoxycarbonyl(C₁₋₆)alkyl, aryl, oxy groups, ureido, guanidino, sulphonylamino, aminosulphonyl, (C₁₋₆)alkylthio,

(C₁-6)alkylsulphinyl, (C₁-6)alkylsulphonyl, heterocyclyl and heterocyclyl(C₁-6)alkyl.

In a particular aspect of the invention, R is hydroxy, R¹ is 1- or 2-naphthylmethyl; and/or R² is benzyl or t-butyl; and/or R³ is hydrogen or 5 methyl. In a further aspect of the invention, R is hydroxy, R¹ is optionally substituted, for example para-substituted, benzyl; R² is t-butyl; and R³ is hydrogen or methyl. In a still further aspect of the invention, each of R to R³ is selected from the group consisting of the values ascribed to it in the Examples hereinbelow. Preferably, the compound of formula (I) of the invention is selected 10 from the group consisting of the compounds described in the Examples hereinbelow.

According to a further aspect, the present invention provides the use of a compound of formula (I) for the production of a medicament for the treatment or prophylaxis of disorders such as allergy, inflammatory disorders and autoimmune 15 disease in which the overproduction of s-CD23 is implicated.

In a further aspect the invention provides a method for the treatment or prophylaxis of disorders such as allergy, inflammatory disorders and autoimmune disease in which the overproduction of s-CD23 is implicated, which method comprises the administration of a compound of formula (I), to a human or non- 20 human mammal in need thereof.

The invention also provides a pharmaceutical composition for the treatment or prophylaxis of disorders such as allergy, inflammatory disorders and autoimmune disease in which the overproduction of s-CD23 is implicated which comprises a compound of formula (I) and optionally a pharmaceutically 25 acceptable carrier therefor.

According to a further aspect, the present invention provides the use of a compound of formula (I) for the production of a medicament for the treatment or prophylaxis of conditions mediated by TNF, including, but not limited to, 30 inflammation, fever, cardiovascular effects, haemorrhage, coagulation and acute phase response, cachexia and anorexia, acute infections, shock states, graft versus host reactions and autoimmune disease.

In a further aspect the invention provides a method for the treatment or prophylaxis of conditions mediated by TNF, which method comprises the administration of a compound of formula (I), to a human or non-human mammal in need thereof.

5 The invention also provides a pharmaceutical composition for the treatment or prophylaxis of conditions mediated by TNF, which comprises a compound of formula (I) and optionally a pharmaceutically acceptable carrier therefor.

10 In a further aspect the invention provides a method for the treatment or prophylaxis of disorders such as allergy, inflammatory disorders and autoimmune disease in which the overproduction of s-CD23 is implicated, which method comprises the administration to a human or non-human mammal in need thereof of a compound which is an inhibitor of the processing of TNF, with the proviso that the compound is not an inhibitor of a matrix metalloprotease.

15 Particular inflammatory disorders include CNS disorders such as Alzheimers disease, multiple sclerosis, and multi-infarct dementia, as well as the inflammation mediated sequelae of stroke and head trauma.

20 It is to be understood that the pharmaceutically acceptable salts, solvates and other pharmaceutically acceptable derivatives of the compound of formula (I) are also included in the present invention.

25 Salts of compounds of formula (I) include for example acid addition salts derived from inorganic or organic acids, such as hydrochlorides, hydrobromides, hydroiodides, p-toluenesulphonates, phosphates, sulphates, acetates, trifluoroacetates, propionates, citrates, maleates, fumarates, malonates, succinates, lactates, oxalates, tartarates and benzoates.

Salts may also be formed with bases. Such salts include salts derived from inorganic or organic bases, for example alkali metal salts such as sodium or potassium salts, and organic amine salts such as morpholine, piperidine, dimethylamine or diethylamine salts.

30 It has surprisingly been found that the compounds of the present invention are potent and selective inhibitors of CD23 processing and TNF release, whilst


exhibiting reduced collagenase inhibitory activity in comparison with the above-mentioned compounds of the prior art.

The compounds of the invention may be prepared by use of any appropriate conventional method, for example by analogy with the methods disclosed in patent publication GB 2 268 934.

5 Accordingly, a further aspect of the invention provides a process for preparing a compound of formula (I) as defined hereinabove, which process comprises:


(a) deprotecting a compound of formula (II):

10




wherein R to R³ are as defined hereinabove, and X is a protecting group such as benzyl or trimethylsilyl or

15 (b) reacting a compound of formula (III):



wherein R to R³ are as defined hereinabove, and any hydroxy group is optionally 20 protected, with hydroxylamine or a salt thereof, or

(c) reacting a compound of formula (IV):



wherein R¹ to R³ are as defined hereinabove, with a thiol to give a compound of formula (I) wherein R is methyl substituted by alkylthio, arylthio, aralkylthio, or heterocyclithio, or

5 (d) converting a compound of formula (I) to a different compound of formula (I) as defined hereinabove.


Compounds of formulae (II) and (III), wherein R is hydroxy or protected hydroxy, and compounds of formula (IV), wherein R¹ is heterocyclmethyl, are novel and form a further aspect of the invention.

10 Compounds of formula (II) can be prepared from compounds of formula (III) by reaction with a protected hydroxylamine. Compounds of formula (III) having one or more protected hydroxy groups can be converted by hydrolysis to a corresponding unprotected compound of formula (III).

Suitable protecting groups for a hydroxamic acid are well known in the art and include benzyl, trimethylsilyl, t-butyl and t-butyldimethylsilyl.

15 Suitable protecting groups for a carboxylic acid are well known in the art and include t-butyl, benzyl and methyl.

Certain compounds of formula (III) can be prepared by reduction of a compound of formula (V):




20

(V)

wherein R¹ to R³ are as defined hereinabove, Y is a protecting group such as t-butyl, and Z is a group such that ZCH₂- is R.


25 Compounds of formula (III) can also be prepared by reacting a compound of formula (VI):



(VI)

wherein R, R¹ and Y are as defined hereinabove, with a compound of formula (VII):


5



(VII)

wherein R² and R³ are as defined hereinabove, or an activated derivative thereof.

10 Compounds of formula (III) can also be prepared by reacting a compound of formula (VIII):




(VIII)

15 wherein R¹ to R³ are as hereinabove defined, with a thiol to give a compound of formula (III) wherein R is methyl substituted by alkylthio, arylthio, aralkylthio, or heterocyclithio.

Compounds of formula (VIII) can be prepared by reacting a compound of formula (IX):


20



(IX)

wherein R¹ and Y are as defined hereinabove, with a compound of formula (VII) as defined hereinabove, or an activated derivative thereof, followed by hydrolysis to remove the protecting group Y.

5 A specific aspect of the invention provides a process for preparing a compound of formula (I) as defined hereinabove wherein R is hydroxy, which process comprises reacting a compound of formula (X):




(X)

10 wherein R¹ to R³ are as defined hereinabove, and R⁴ and R⁵ are the same or different and each is hydrogen or a hydroxy protecting group, or R⁴ and R⁵ together form a divalent hydroxy protecting group, with hydroxylamine or a salt thereof.

15 Compounds of formula (X) wherein R⁴ and R⁵ are hydrogen can be prepared by deprotection (eg hydrolysis and/or deetherification) of a corresponding compound wherein R⁴ and R⁵ are not hydrogen.

Compounds of formula (X) wherein R⁴ and R⁵ are not hydrogen can be prepared by reacting a compound of formula (XI):




(XI)

20

wherein R¹, R⁴ and R⁵ are as defined hereinabove, with a compound of formula (VII) as defined hereinabove.

25 Preferred compounds of formula (IX) can be prepared by reacting a compound of formula (XII):




(XII)

wherein R¹ is as defined hereinabove, with dimethoxypropane.

5 Compounds of formula (XII) can be prepared by reacting a diester (such as the dimethyl or diethyl ester) of 2-hydroxy succinic acid with a compound of formula R¹X' in the presence of a strong base such as lithium diisopropylamide, wherein X' is a leaving group such as bromine or iodine, and then hydrolysing the resulting compound to remove the ester groups.

10 The isomers, including stereoisomers, of the compounds of the present invention may be prepared as mixtures of such isomers or as individual isomers. The individual isomers may be prepared by any appropriate method, for example individual stereoisomers may be prepared by stereospecific chemical synthesis starting from chiral substrates or by 15 separating mixtures of diastereoisomers using known methods. In a preferred aspect, the invention provides compounds of formula (IA):



(IA)

20 It is preferred that the compounds are isolated in substantially pure form.

As stated herein an inhibitor of the formation of soluble human CD23 has useful medical properties. Preferably the active compounds are administered as pharmaceutically acceptable compositions.

25 The compositions are preferably adapted for oral administration. However, they may be adapted for other modes of administration, for example in the form of a spray, aerosol or other conventional method for inhalation, for treating respiratory tract disorders; or parenteral

administration for patients suffering from heart failure. Other alternative modes of administration include sublingual or transdermal administration.

The compositions may be in the form of tablets, capsules, powders, granules, lozenges, suppositories, reconstitutable powders, or liquid

5 preparations, such as oral or sterile parenteral solutions or suspensions.

In order to obtain consistency of administration it is preferred that a composition of the invention is in the form of a unit dose.

Unit dose presentation forms for oral administration may be tablets and capsules and may contain conventional excipients such as binding

10 agents, for example syrup, acacia, gelatin, sorbitol, tragacanth, or polyvinylpyrrolidone; fillers, for example lactose, sugar, maize-starch, calcium phosphate, sorbitol or glycine; tabletting lubricants, for example magnesium stearate; disintegrants, for example starch,

polyvinylpyrrolidone, sodium starch glycollate or microcrystalline

15 cellulose; or pharmaceutically acceptable wetting agents such as sodium lauryl sulphate.

The solid oral compositions may be prepared by conventional methods of blending, filling or tabletting. Repeated blending operations may be used to distribute the active agent throughout those compositions

20 employing large quantities of fillers. Such operations are of course conventional in the art. The tablets may be coated according to methods well known in normal pharmaceutical practice, in particular with an enteric coating.

Oral liquid preparations may be in the form of, for example,

25 emulsions, syrups, or elixirs, or may be presented as a dry product for reconstitution with water or other suitable vehicle before use. Such liquid preparations may contain conventional additives such as suspending agents, for example sorbitol, syrup, methyl cellulose, gelatin, hydroxyethylcellulose, carboxymethylcellulose, aluminium stearate gel,

30 hydrogenated edible fats; emulsifying agents, for example lecithin, sorbitan monooleate, or acacia; non-aqueous vehicles (which may include edible oils), for example almond oil, fractionated coconut oil, oily esters such as

esters of glycerine, propylene glycol, or ethyl alcohol; preservatives, for example methyl or propyl p-hydroxybenzoate or sorbic acid; and if desired conventional flavouring or colouring agents.

- For parenteral administration, fluid unit dosage forms are prepared
- 5 utilizing the compound and a sterile vehicle, and, depending on the concentration used, can be either suspended or dissolved in the vehicle. In preparing solutions the compound can be dissolved in water for injection and filter sterilized before filling into a suitable vial or ampoule and sealing. Advantageously, adjuvants such as a local anaesthetic, a preservative and
- 10 buffering agents can be dissolved in the vehicle. To enhance the stability, the composition can be frozen after filling into the vial and the water removed under vacuum. Parenteral suspensions are prepared in substantially the same manner, except that the compound is suspended in the vehicle instead of being dissolved, and sterilization cannot be
- 15 accomplished by filtration. The compound can be sterilized by exposure to ethylene oxide before suspending in the sterile vehicle. Advantageously, a surfactant or wetting agent is included in the composition to facilitate uniform distribution of the compound.

- Compositions of this invention may also suitably be presented for
- 20 administration to the respiratory tract as a snuff or an aerosol or solution for a nebulizer, or as a microfine powder for insufflation, alone or in combination with an inert carrier such as lactose. In such a case the particles of active compound suitably have diameters of less than 50 microns, preferably less than 10 microns for example diameters in the range
- 25 of 1-50 microns, 1-10 microns or 1-5 microns. Where appropriate, small amounts of other anti-asthmatics and bronchodilators, for example sympathomimetic amines such as isoprenaline, isoetharine, salbutamol, phenylephrine and ephedrine; xanthine derivatives such as theophylline and aminophylline and corticosteroids such as prednisolone and adrenal
- 30 stimulants such as ACTH may be included.

The compositions may contain from 0.1% to 99% by weight, preferably from 10-60% by weight, of the active material, depending upon

the method of administration. A preferred range for inhaled administration is 10-99%, especially 60-99%, for example 90, 95 or 99%.

Microfine powder formulations may suitably be administered in an aerosol as a metered dose or by means of a suitable breath-activated device.

5 Suitable metered dose aerosol formulations comprise conventional propellants, cosolvents, such as ethanol, surfactants such as oleyl alcohol, lubricants such as oleyl alcohol, desiccants such as calcium sulphate and density modifiers such as sodium chloride.

10 Suitable solutions for a nebulizer are isotonic sterilised solutions, optionally buffered, at for example between pH 4-7, containing up to 20mg/ml of compound but more generally 0.1 to 10mg/ml, for use with standard nebulisation equipment.

15 An effective amount will depend on the relative efficacy of the compounds of the present invention, the severity of the disorder being treated and the weight of the sufferer. Suitably, a unit dose form of a composition of the invention may contain from 0.1 to 1000mg of a compound of the invention (0.001 to 10mg via inhalation) and more usually from 1 to 500mg, for example 1 to 25 or 5 to 500mg. Such compositions may be administered from 1 to 6 times a day, more usually from 2 to 4 times a day, in a manner such that the daily dose is from 1mg to 1g for a 70 kg human adult and more particularly from 5 to 500mg. That is in the range of about 1.4×10^{-2} mg/kg/day to 14 mg/kg/day and more particularly in the range of about 7×10^{-2} mg/kg/day to 7 mg/kg/day.

20 The following examples illustrate the invention but do not limit it in any way.

BIOLOGICAL TEST METHODS

Procedure 1: The ability of test compounds to inhibit the release of soluble CD23 was investigated by use of the following procedure.

5

RPMI 8866 Cell membrane CD23 cleavage activity assay:

Plasma membranes from RPMI 8866 cells, a human Epstein-Barr virus transformed B-cell line (Sarfati et al., *Immunology* 60 [1987] 539-547)

- 10 expressing high levels of CD23 are purified using an aqueous extraction method. Cells resuspended in homogenization buffer (20mM HEPES pH 7.4, 150 mM NaCl, 1.5 mM MgCl₂, 1 mM DTT) are broken by N₂ cavitation in a Parr bomb and the plasma membrane fraction mixed with other membranes is recovered by centrifugation at 10,000Xg. The light pellet is resuspended in 0.2 M potassium phosphate, pH 7.2 using 2 ml per 1-3 g wet cells and the nuclear pellet is discarded. The membranes are further fractionated by partitioning between Dextran 500 (6.4% w/w) and polyethylene glycol (PEG) 5000 (6.4% w/w) (ref), at 0.25 M sucrose in a total of 16 g per 10-15 mg membrane proteins [Morre and Morre, *BioTechniques* 7, 946-957 (1989)]. The phases are separated by brief 15 centrifugation at 1000Xg and the PEG (upper) phase is collected, diluted 3-5 fold with 20 mM potassium phosphate buffer pH 7.4, and centrifuged at 100,000Xg to recover membranes in that phase. The pellet is resuspended in phosphate-buffered saline and consists of 3-4 fold enriched plasma membranes as well as some other cell membranes (e.g. lysosomes, Golgi). The membranes are 20 aliquoted and stored at -80°C. Fractionation at 6.6 % Dextran/PEG yields plasma membranes enriched 10-fold.
- 25

The fractionated membranes are incubated at 37°C for times up to 4 hrs to produce fragments of CD23 which are separated from the membrane by filtration in 0.2 micron Durapore filter plates (Millipore) after quenching the assay with 5

- 30 uM Preparation 1 from P 30994. sCD23 released from the membrane is determined using the EIA kit from The Binding Site (Birmingham, UK) or a similar one utilizing MHM6 anti-CD23 mAb [Rowe et al., *Int. J. Cancer*, 29, 373-

382 (1982)] or another anti-CD23 mAb as the capture antibody in a sandwich EIA.. The amount of soluble CD23 made by 0.5 ug membrane protein in a total volume of 50 ul phosphate-buffered saline is measured by EIA and compared to the amount made in the presence of various concentrations of inhibitors.

- 5 Inhibitors are prepared in solutions of water or dimethylsulfoxide (DMSO) and the final DMSO concentration is not more than 2 %. IC50's are determined by curve fitting as the concentration where 50 % inhibition of production of sCD23 is observed relative to the difference in sCD23 between controls incubated without inhibitor.

10

Procedure 2: The ability of test compounds to inhibit collagenase was investigated using the following procedure.

Collagenase inhibition assay:

15

The potency of compounds to act as inhibitors of collagenase was determined by the method of Cawston and Barrett (Anal. Biochem. 99, 340-345, 1979), hereby incorporated by reference, whereby a 1 mM solution of the inhibitor being tested or dilutions thereof, was incubated at 37 °C for 18 h with collagen and human

- 20 recombinant collagenase, from synovial fibroblasts cloned, expressed and purified from E. Coli, (buffered with 150 mM Tris, pH 7.6, containing 15 mM calcium chloride, 0.05% Brij 35, 200 mM sodium chloride and 0.02% sodium azide). The collagen was acetylated ³H type 1 bovine collagen prepared by the method of Cawston and Murphy (methods in Enzymology 80, 711,1981) The samples were
25 centrifuged to sediment undigested collagen and an aliquot of the radioactive supernatant removed for assay on a scintillation counter as a measure of hydrolysis. The collagenase activity in the presence of 1mM inhibitor, or dilution thereof, was compared to activity in a control devoid of inhibitor and the results reported as that concentration effecting 50% of the collagenase (IC₅₀).

30

Procedure 3: The ability of test compounds to inhibit TNF release was investigated using the following procedure.

Assay for inhibition of release of TNF α from human monocytes stimulated

5 by lipopolysaccharide (LPS) endotoxin.


Human monocytes, cultured in RPMI 1640 medium supplemented with 10 % fetal calf serum, are centrifuged at 1000Xg for 5 min and then resuspended in medium at 2×10^6 cells/ ml. The cell suspension is aliquoted in 24 well plates, 10 1 ml per well. Compounds to be tested are dissolved in neat dimethyl sulfoxide (DMSO) and added to culture with the final DMSO concentration at 0.1 %. Compounds are added to cells in triplicate wells. TNF α release is stimulated by addition of LPS to the cells at a final concentration of 200 ng/ml. Appropriate control cultures are set up in triplicates also. The plates are incubated for 18-20 15 hrs at 37° C, 5% CO₂, then centrifuged at 1000 Xg for 5 min. A specific ELISA for human TNF α (SmithKline Beecham) is used to measure TNF levels in the cell-free culture supernatants.

Example 1

Preparation of N'-[3S-Hydroxy-4-(N-hydroxyamino)-2R-(2-naphthylmethyl)succinyl]-S-tert-leucine-N-methylamide.

5

a) Dimethyl 2S-hydroxy-3R-(2-naphthylmethyl)succinate




10

- To a solution of diisopropylamine (3.1 ml, 22 mmol) in tetrahydrofuran (30 ml) at -10° C was added dropwise n-butyllithium (1.6M in hexane, 13.75 ml, 22 mmol). The solution was stirred for 30 min then cooled to -70° and a solution of (S)-dimethyl malate (1.6 g, 10 mmol) in tetrahydrofuran (20 ml) added dropwise.
- 15 After 90 min 2-naphthylmethyl bromide (4.42 g, 22 mmol) was added. The reaction was stirred for 2 h then poured into 2N hydrochloric acid and the product extracted with diethyl ether (3x50 ml). The combined extracts were washed with water (30, ml), sodium bicarbonate (30 ml), brine and dried (MgSO_4). Filtration and evaporation gave an oil which was chromatographed on silica. Gradient elution (0-50% ether/hexane) gave (1.08 g) as a white solid mp 91-92° C.
- 20

$^1\text{H NMR}$ (CDCl_3) 3.13-3.47 (3H, m), 3.26 (1H, d, $J = 7\text{Hz}$), 3.69 (3H, s), 3.74 (3H, s), 4.12 (1H, dd, $J = 7, 2.5\text{ Hz}$), 7.38-7.50 (3H, m), 7.73 (1H, s), 7.81 (4H, br d, $J = 8\text{Hz}$).


b) N'-[2R-(2,2-Dimethyl-4-oxo-1,3-dioxolan-5S-yl)-3-(2-naphthyl)propanoyl]-S-tert-leucine-N-methylamide



- 5 To a solution of dimethyl 2S-hydroxy-3R-(2-naphthylmethyl)succinate (2.0 g, 6.6 mmol) in dioxane (15 ml) and water (30 ml) was added potassium hydroxide (1.11 g). The yellow solution was heated under reflux for 3 h, acidified using Dowex 50x8 resin and concentrated. The resulting pink solid was dissolved in dimethyl formamide (50 ml) and 2,2-dimethoxypropane (50 ml) and tosyl chloride (0.1 g) added. After stirring for 18 h the solution was concentrated. The residue was dissolved in ethyl acetate and washed with sodium bicarbonate solution, dried ($MgSO_4$) and concentrated to a yellow foam (1.664 g). This was dissolved in dry dimethyl formamide (10 ml) and 1-hydroxybenzotriazole hydrate (367 mg), tert leucine methylamide (218mg, 1.5 mmol) and 1-(3-
- 10 dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (312 mg, 1.6 mmol) were added. The solution was stirred for 18 h then concentrated. The residue was dissolved in ethyl acetate and washed with citric acid (10%, 2x20 ml), water (20 ml), sodium bicarbonate solution (20 ml) and brine (10 ml) and dried ($MgSO_4$). Removal of the solvent and chromatography of the residue on silica (diethyl ether) gave N'-[2R-(2,2-dimethyl-4-oxo-1,3-dioxolan-5S-yl)-3-(2-naphthyl)propanoyl]-S-tert-leucine-N-methylamide (434 mg) as a white powder mp 118-9 ° C.
- 15 1H NMR (d_6 DMSO) 0.84 (9H,s), 1.49 (3H,s), 1.59 (3H,s), 2.33 (3H, d, J = 4.5 Hz), 3.0-3.24 (2H,m), 4.16 (1H,d, J = 10Hz), 4.55 (1H, d, J = 8.5 Hz), 7.33 (1H, d, J = 7 Hz), 7.4-7.5 (2H, m), 7.65 (1H, s), 7.67-7.86 (5H, m).

c) N'-[3S-Hydroxy-4-(N-hydroxyamino)-2R-(2-naphthylmethyl)succinyl]-S-tert-leucine-N-methylamide.


5



- A solution of N'-[2R-(2,2-dimethyl-4-oxo-1,3-dioxolan-5S-yl)-3-(2-naphthyl)propanoyl]-S-tert-leucine-N-methylamide (410 mg, 0.9 mmol), hydroxylamine hydrochloride (259 mg, 3.7 mmol) and N-methylmorpholine 10 (0.41 ml, 3.7 mmol) in methanol (5 ml) was stirred for 24 h. The solution was concentrated, triturated with diethyl ether, water and then filtered to give N'-[3S-hydroxy-4-(N-hydroxyamino)-2R-(2-naphthylmethyl)succinyl]-S-tert-leucine-N-methylamide as a white solid (257 mg) mp 189-90 °C.
- 15 ¹H NMR (d_6 DMSO) 0.85(9H,s), 2.25 (3H, d, J = 4.5 Hz), 2.74 (1H, dd, J = 13.4, 5 Hz), 2.94 (1H, app t, J = 11Hz), 3.07-3.09 (1H, m), 3.86 (1H, t, J = 7.5 Hz), 4.09 (1H,d, J = 10Hz), 5.55 (1H, d, J = 8 Hz), 7.29 (1H, d, J = 8 Hz), 7.4-7.51 (3H, m), 7.51 (1H, s), 7.75-7.85 (4H, m), 8.89 (1H, s) 10.67 (1H, s).
- 20 The following compounds were prepared using the method described in Example 1:

Example 2


5 N'-[3S-Hydroxy-4-(N-hydroxyamino)-2R-(2-naphthylmethyl)succinyl]-S-phenylalanine-N-methylamide



10 mp 168-70 °C. ^1H NMR (d_6 DMSO) 2.28 (3H, d, $J = 4$ Hz), 2.77-2.96 (5H, m), 3.94 (1H, t, $J = 4$ Hz), 4.27 (1H, q, $J = 5$ Hz), 5.77 (1H, d, $J = 6$ Hz), 7.1-7.87 (13H, m), 7.98 (1H, d, $J = 7.5$ Hz), 8.93 (1H, s) 10.74 (1H, s).

Example 3

15 N'-[3S-Hydroxy-4-(N-hydroxyamino)-2R-(2-naphthylmethyl)succinyl]-S-phenylalaninamide



mp 175-7 °C. ^1H NMR (d_6 DMSO) 2.75-3.0 (4H, m), 3.01 (1H, dd, J = 13.5, 5 Hz), 3.93 (1H, t, J = 6Hz), 4.26 (1H,dd, J = 8, 5.5 Hz), 5.82 (1H, d, J = 6 Hz), 7.02 (1H, br s), 7.16 (5H, s), 7.22 (2H, d, J = 10 Hz), 7.41-7.50 (2H, m), 7.55 (1H, br s), 7.75-7.86 (3H, m), 7.95 (1H, d, J = 8 Hz), 8.91 (1H, s) 10.70 (1H, s).

5

Example 4

N' -[3S-Hydroxy-4-(N-hydroxyamino)-2R-(3-iodobenzyl)succinyl]-S-phenylalaninamide MH^+ 512

10

Example 5

N' -[3S-Hydroxy-4-(N-hydroxyamino)-2R-(4-methylbenzyl)succinyl]-S-phenylalaninamide MNa^+ 422

15

Example 6

N' -[3S-Hydroxy-4-(N-hydroxyamino)-2R-(3-methylbenzyl)succinyl]-S-phenylalaninamide MNa^+ 422

20

Example 7

N' -[3S-Hydroxy-4-(N-hydroxyamino)-2R-(benzyl)succinyl]-S-phenylalaninamide MNa^+ 408

25

Example 8

N' -[3S-Hydroxy-4-(N-hydroxyamino)-2R-(2-methylbenzyl)succinyl]-S-phenylalanine N-methylamide MH^+ 414

Example 9

N'-[3S-Hydroxy-4-(N-hydroxyamino)-2R-(benzyl)succinyl]-S-phenylalanine N-methylamide MH^+ 400

5

Example 10

N'-[3S-Hydroxy-4-(N-hydroxyamino)-2R-(2-phenylbenzyl)succinyl]-S-phenylalanine N-methylamide MNa^+ 498

10

Example 11

N'-[3S-Hydroxy-4-(N-hydroxyamino)-2R-(3-iodobenzyl)succinyl]-S-tert-leucine N-methylamide MH^+ 492

15

Example 12

N'-[3S-Hydroxy-4-(N-hydroxyamino)-2R-(4-methylbenzyl)succinyl]-S-tert-leucine N-methylamide MH^+ 380

20

Example 13

N'-[3S-Hydroxy-4-(N-hydroxyamino)-2R-(3-methylbenzyl)succinyl]-S-tert-leucine N-methylamide MH^+ 380

25

Example 14

N'-[3S-Hydroxy-4-(N-hydroxyamino)-2R-(benzyl)succinyl]-S-tert-leucine N-methylamide MH^+ 366

30


Example 15

10 **N'-[3S-Hydroxy-4-(N-hydroxyamino)-2R-(4-azidobenzyl)succinyl]-S-tert-leucine-N-methylamide** MH^+ 407

5

Example 16

10 **N'-[3S-Hydroxy-4-(N-Hydroxyamino)-2-R-(2-Benzothiophenylmethyl)succinyl]- S-phenylalanamide**




15

15 **m.p. 189-190 °C. 1H NMR, (d⁶ DMSO) 2.8-3.14 (5H, m), 4.00 (1H, t, $J = 6.5$ Hz), 4.31 (1H, dd, $J = 5.3$ Hz), 5.85 (1H, d, $J = 6.5$ Hz), 6.97 (1H, s), 7.06 (1H, br s), 7.15 (5H, S), 7.24-7.32 (2H, m), 7.34 (1H, br s), 7.67 (1H, d, $J = 7$ Hz), 7.84 (1H, d, $J = 7$ Hz), 7.99 (1H, d, $J = 8$ Hz), 8.93 (1H, d, $J = 2$ Hz), 10.70 (1H, d, $J = 2$ Hz).**

20

Example 17

25 **N'-[3S-Hydroxy-4-(N-Hydroxyamino)-2-R-(3-Benzothiophenylmethyl)succinyl]- S-phenylalanine-N-methylamide**




m.p. 148-150°C. $MH^+ = 456$; $MNa^+ = 478$.

5

Example 18


10 N' -[3S-Hydroxy-4-(N-Hydroxyamino)-2-R-(2-Benzofuranyl methyl) succinyl]-S-phenylalanine-N-methylamide



15 m.p. 160-161 °C. 1H NMR, (d^6 DMSO) 2.43 (3H, d, $J = 4$ Hz), 2.75-3.10 (5H, m), 4.01 (1H, t, $J = 6$ Hz), 4.33 (1H, app q, $J = 5.5$ Hz), 5.86 (1H, d, $J = 6$ Hz), 6.40 (1H, s), 7.02-7.25 (7H, m), 7.44-7.50 (2H, m), 7.66 (1H, q, $J = 4$ Hz), 8.07 (1H, d, $J = 6$ Hz), 8.94 (1H, s), 10.75 (1H, s).

20 **Example 19**

25 N' -[3S-Hydroxy-4-(N-Hydroxyamino)-2-R-(4-Hydroxybenzyl) succinyl]-S-phenylalanine




5 m.p. 154-155°C. 1H NMR, (d⁶ DMSO) 2.49-2.58 (2H, obs), 2.66 (1H, dd, J = 14.8 Hz), 2.84 (1H, dd, J = 14.8 Hz), 3.08 (1H, dd, J = 14.5 Hz), 3.85 (1H, t, J = 6.5 Hz), 4.27 (1H, m), 5.74 (1H, d, J = 6.5 Hz), 6.58 (2H, d, J = 8 Hz), 6.81 (2H, d, J = 8 Hz), 7.05 (1H, br s), 7.15-7.26 (6H, m), 7.83 (1H, d, J = 8 Hz), 8.86 (1H, s), 9.14 (1H, s), 10.64 (1H, s).

10

Example 20

15

N'-[3S-Hydroxy-4-(N-Hydroxyamino)-2-R-(7-Methoxybenzofuranyl methyl) succinyl]- S-phenylalanine-N-methylamide




20

m.p. 161-163°C. $MH^+ = 470$; $MNa^+ = 492$.

Example 21


5 **N'-[3S-Hydroxy-4-(N-Hydroxyamino)-2-R-(2-(3-Methyl)benzothiophenylmethyl) succinyl]- S-phenylalanine-N-methylamide**



15 $MH^+ = 470$; $MNa^+ = 492$.

Example 22

20 **N'-[3S-Hydroxy-4-(N-Hydroxyamino)-2-R-(4-Benzyloxybenzyl) succinyl]- S-phenylalanamide**




5 m.p. 179-180°C (methanol/ethyl acetate). ^1H NMR, (d^6 DMSO) 2.5-2.93 (4H, m), 3.02 (1H, dd, $J = 14,5$ Hz), 3.86 (1H, t, $J = 6$ Hz), 4.28 (1H, dd, $J = 14,5$ Hz), 5.03 (2H, s), 5.72 (1H, d, $J = 6$ Hz), 6.83 (2H, d, $J = 8.5$ Hz), 6.93 (2H, d, $J = 8.5$ Hz), 7.04 (1H, s), 7.08 (1H, s), 7.1-7.3 (5H, m), 7.3-7.5 (5H, m), 7.86 (1H, d, $J = 8$ Hz), 8.86 (1H, s), 10.64 (1H, s).

10 **Example 23**

15

N'-[3S-Hydroxy-4-(N-Hydroxyamino)-2-R-(3,4-Dimethylbenzyl) succinyl]- S-phenylalanine-N-methylamide

20




25

m.p. 163-165°C. $\text{MH}^+ = 428$.

25 **Example 24**

30

N'-[3S-Hydroxy-4-(N-Hydroxyamino)-2-R-(4-(prop-2-yl)benzyl) succinyl]- S-phenylalanamide




m.p. 168-170°C. $MNa^+ = 450$.

5

Example 25

- 10 ***N'*-[3S-Hydroxy-4-(N-hydroxyamino)-2R-(2-benzthiazazylmethyl)succinyl]-S-tert-leucine N-methylamide**




15

- m.p. 132-134°C. 1H NMR, (d^6 DMSO) 0.86 (9H, s), 2.39 (3H, d, $J = 4.5$ Hz), 2.5-2.6 (1H, obs), 3.0-3.24 (2H, m), 3.95 (1H, t, $J = 3$ Hz), 4.15 (1H, d, $J = 8$ Hz), 7.4-7.7 (3H, m), 7.75 (1H, br q, $J = 4.5$ Hz), 7.88 (1H, d, $J = 9$ Hz), 8.94 (1H, s), 10.73 (1H, s).

Example 26

25

- N'*-[3S-Hydroxy-4-(N-Hydroxyamino)-2-R-(2-benzthiazazylmethyl)succinyl]-S-phenylalanamide**




5 m.p. 165-167°C. 1H NMR, (d^6 DMSO) 2.88 (1H, dd, J = 14,8 Hz), 3.01-3.22 (4H, m), 4.06 (1H, app t, J = 6.5 Hz), 4.28 (1H, dd, J = 8,3 Hz), 5.80 (1H, d, J = 6 Hz), 7.05-7.15 (6H, m), 7.38-7.51 (3H, m), 7.89 (1H, d, J = 8 Hz), 8.02 (1H, d, J = 7 Hz), 8.08 (1H, d, J = 8 Hz), 8.95 (1H, s), 10.71 (1H, s).

10

Example 27

15 N^1 -[3S-Hydroxy-4-(N-hydroxyamino)-2R-{2-(4-nitrobenzyl)}succinyl]-S-phenylalanine-N-methylamide




20

$MH^+ = 445$.

Example 28

5 N'-[3S-Hydroxy-4-(N-hydroxyamino)-2R-(2-(4-aminobenzyl))succinyl]-S-phenylalanine-N-methylamide




10

 $M^+ = 414.$ **Example 29**

15


N'-[3S-Hydroxy-4-(N-hydroxyamino)-2R-(2-(4-benzoylaminobenzyl))succinyl]-S-phenylalanine-N-methylamide

20

 $MNa^+ = 541.$

Example 30

5 N'-[3S-Hydroxy-4-(N-hydroxyamino)-2R-{2RS-(1,2,3,4-tetrahydronaphthylmethyl)}succinyl]-S-phenylalanine-N-methylamide



10

 $MNa^+ = 476$


1H NMR (d_6 DMSO) 1.07-1.45(2H, m), 1.49-1.67(2H, m), 2.10-2.31(1H, m), 2.46(3H, d, $J = 4.4$ Hz, collapses to a singlet with D_2O), 2.51-2.65(4H, m), 2.81-2.87(2H, m), 3.06(1H, d,d, $J = 4.2$ & 8.0Hz), 3.89(1H, t, $J = 7.3$ Hz, collapses to a

15 doublet, $J = 7.0$ Hz with D_2O), 4.30-4.47(1H, m), 5.65(1/3H, d, $J = 7.2$ Hz, exchanges with D_2O), 5.72(2/3H, d, $J = 7.2$ Hz, exchanges with D_2O), 7.03-7.18(9H, m), 7.80(2/3H, q, $J = 4.3$ Hz, exchanges with D_2O), 7.89(1/3H, q, $J = 4.3$ Hz, exchanges with D_2O), 7.98(1H, d, $J = 8.25$ Hz, exchanges with D_2O), 8.88(1H, s, exchanges with D_2O), 10.66(1H, s, exchanges with D_2O)

20

Example 31

25 N'-[3S-Hydroxy-4-(N-Hydroxyamino)-2-R-(2-naphthylmethyl) succinyl]- S-tert-leucinamide




$MNa^+ = 424$

5 1H NMR (d_6 DMSO) 0.90 (9H, s), 2.75 (1H, dd, $J = 13,5$ Hz), 2.97-3.31 (2H, m), 3.84 (1H, t, $J = 7$ Hz), 4.15 (1H, d, $J = 10$ Hz), 5.61 (1H, d, $J = 8$ Hz), 6.88 (1H, s), 7.242 (1H, s), 7.32 (1H, d, $J = 8$ Hz), 7.45 (2H, m), 7.55 (1H, d, $J = 10$ Hz), 7.63 (1H, m), 7.82 (3H, m), 8.88 (1H, s), 10.68 (1H, s).

10 Example 32

N' -[3S-Hydroxy-4-(N-Hydroxyamino)-2-R-(5-Benzothiophenylmethyl) succinyl]- S-phenylalanine-N-methylamide

15



$MH^+ = 456$, $MNa^+ = 478$

20 1H NMR (d_6 DMSO) 2.36 (3H, d, $J = 4$ Hz), 2.81-3.15 (5H, m), 3.92 (1H, m), 4.30 (1H, m), 5.78 (1H, d, $J = 6$ Hz), 7.05 (1H, d, $J = 8$ Hz); 7.17 (5H, m), 7.35 (2H, d, $J = 5.5$ Hz), 7.52 (1H, s), 7.71 (1H, d, $J = 5$ Hz), 7.83 (1H, d, $J = 8$ Hz), 7.96 (1H, d, $J = 8$ Hz), 8.92 (1H, s), 10.73 (1H, s).


25

Example 33

N' - [3S-Hydroxy-4-(N-hydroxyamino)-2R-(4-biphenylmethyl)succinyl]

-S-phenylalanine-N-methylamide

5


 $MH^+ = 476, MNa^+ = 498$

10 1H NMR (d_6 DMSO) 2.44 (3H, d, $J = 5$ Hz), 2.56-2.87 (4H, m), 3.01 (1H, dd, $J = 13.7, 5$ Hz), 3.93 (1H, t, $J = 6.5$ Hz), 4.31 (1H, m), 5.78 (1H, d, $J = 6$ Hz), 7.10-7.65 (15H, m), 7.97 (1H, d, $J = 8$ Hz), 8.92 (1H, s), 10.72 (1H, s).

15

Example 34

20 $N^*-[3S\text{-Hydroxy-4-(N\text{-Hydroxyamino)-2-R-(2S,5S,6S,7S,8S)-tetrahydronaphthylmethyl)]-S\text{-tert-leucine-N-methylamide}$




25

 $MNa^+ = 442$

Example 35

5 N'-[3S-Hydroxy-4-(N-Hydroxyamino)-2-R-(1-naphthylmethyl) succinyl]- S-tert-
leucine-N-methylamide




10

 $MNa^+ = 438$ **15 Example 36**

20 N'-[3S-Hydroxy-4-(N-hydroxyamino)-2R-(4-benzyl)benzylsuccinyl]-
S-phenylalanine-N-methylamide

20



25

 $MNa^+ = 512$

Example 37

N'-[3S-Hydroxy-4-(N-hydroxyamino)-2R-(2-(3-quinolinyl)methyl)succinyl-S-phenyl-alaninamide.

5

¹H NMR (d₆ DMSO; 400 MHz) 2.83-3.02 (5H, m), 3.97 (1H, br. d), 4.28 (1H, m), 5.81 (1H, br. s), 6.98 (1H, br. s), 7.16 (5H, m), 7.28 (1H, br. m), 7.57 (1H, ddd, J = 8, 7, 1 Hz), 7.70 (1H, ddd, J = 8, 7, 1 Hz), 7.86 (1H, dd, J = 8, 1 Hz), 7.95-7.99 (3H, m), 8.66 (1H, d, J = 2 Hz), 8.91 (1H, br. s), 10.72 (1H, m).

10

Example 38

N'-[3S-Hydroxy-4-(N-hydroxyamino)-2R-(2-(3-quinolinyl)methyl)succinyl-S-tyrosinamide.

15

¹H NMR (d₆ DMSO; 400 MHz) 2.73-2.94 (5H, m), 3.97 (1H, br. t), 4.21 (1H, m), 5.84 (1H, br. d, J = 6 Hz), 6.60 (2H, d, J = 8 Hz), 6.95 (1H, br. s), 6.96 (2H, d, J = 8 Hz), 7.24 (1H, br. s), 7.56 (1H, ddd, J = 8, 7, 1 Hz), 7.69 (1H, ddd, J = 8, 7, 1 Hz), 7.85-7.98 (4H, m), 8.66 (1H, d, J = 2 Hz), 8.91 (1H, br. s), 9.13 (1H, s), 10.73 (1H, s).

20

Example 39

25

N'-[3S-Hydroxy-4-(N-hydroxyamino)-2R-(2-(6,7-difluoronaphthyl)methyl)succinyl-S-tyrosinamide.

30

¹H NMR (d₆ DMSO; 400 MHz) 2.67-2.87 (5H, m), 3.89 (1H, t, J = 6 Hz), 4.16 (1H, m), 5.74 (1H, d, J = 6 Hz), 6.56 (2H, d, J = 8 Hz), 6.90 (1H, br. s), 6.92 (2H, d, J = 8 Hz), 7.04 (1H, br. s), 7.21 (1H, d, J = 8 Hz), 7.51 (1H, s), 7.73-7.92 (4H, m), 8.86 (1H, s), 9.09 (1H, s), 10.66 (1H, s).

35

N'-[3S-Hydroxy-4-(N-hydroxyamino)-2R-(2-(6-hydroxynaphthyl)methyl)succinyl-S-phenylalaninamide

40

¹H NMR (d₆ DMSO; 400 MHz) 2.69-2.88 (4H, m), 3.01 (1H, dd, J = 14, 4 Hz), 3.90 (1H, t, J = 6 Hz), 4.26 (1H, m), 5.83 (1H, d, J = 6 Hz), 7.02-7.25 (10 H, m), 7.40 (1H, s), 7.53 (1H, d, J = 8 Hz), 7.62 (1H, d, J = 9 Hz), 7.95 (1H, d, J = 8 Hz), 8.93 (1H, s), 9.64 (1H, s), 10.72 (1H, s).

Example 41

N'-[3S-Hydroxy-4-(N-hydroxyamino)-2R-(2-(6-fluoronaphthyl)methyl)succinyl-S-phenylalaninamide

5

mp 198-201°C; ^1H NMR (d_6 DMSO; 400 MHz) 2.74-2.93 (4H, m), 3.01 (1H, dd, J = 14, 5 Hz), 3.93 (1H, t, J = 6 Hz), 4.27 (1H, m), 5.78 (1H, d, J = 6 Hz), 6.98 (1H, br. s), 7.16 (6H, m), 7.26 (1H, d, J = 8 Hz), 7.37 (1H, m), 7.59 (1H, s), 7.63 (1H, dd, J = 12, 2 Hz), 7.76 (1H, d, J = 9 Hz), 7.86 (1H, m), 7.93 (1H, d, J = 8 Hz), 8.90 (1H, s), 10.69 (1H, s).

10

Example 42

N'-[3S-Hydroxy-4-(N-hydroxyamino)-2R-(2-(7-fluoronaphthyl)methyl)succinyl-S-phenylalaninamide.

15

mp 197-8°C; ^1H NMR (d_6 DMSO; 400 MHz) 2.76-2.93 (4H, m), 3.01 (1H, dd, J = 14, 5 Hz), 3.93 (1H, t, J = 6 Hz), 4.28 (1H, m), 5.77 (1H, d, J = 7 Hz), 6.99 (1H, br. s), 7.17 (7H, m), 7.34 (1H, m), 7.55 (2H, m), 7.80 (1H, d, J = 8 Hz), 7.92 (2H, m), 8.90 (1H, s), 10.69 (1H, s).

20

Example 43

N'-[3S-Hydroxy-4-(N-hydroxyamino)-2R-(2-(6-quinolinyl)methyl)succinyl-S-phenylalaninamide.

25

mp 215-20°C; ^1H NMR (d_6 DMSO; 400 MHz) 2.80-2.96 (4H, m), 3.01 (1H, dd, J = 14, 5 Hz), 3.95 (1H, t, J = 6 Hz), 4.28 (1H, m), 5.79 (1H, d, J = 6 Hz), 6.99 (1H, br. s), 7.15 (5H, m), 7.23 (1H, br. s), 7.44-7.50 (2H, m), 7.60, (1H, s), 7.87 (1H, d, J = 9 Hz), 7.95 (1H, d, J = 8 Hz), 8.23 (1H, d, J = 8 Hz), 8.83 (1H, dd, J = 4, 1 Hz), 8.91 (1H, s), 10.70 (1H, s).

30

Example 44

N'-[3S-Hydroxy-4-(N-hydroxyamino)-2R-(2-(6-benzyloxynaphthyl)methyl)succinyl-S-phenylalaninamide

35

mp 201-4°C; ^1H NMR (d_6 DMSO; 400 MHz) 2.75 (1H, m), 2.83-2.91 (3H, m), 3.01 (1H, dd, J = 14, 5 Hz), 3.95 (1H, t, J = 6 Hz), 4.28 (1H, ddd, J = 8, 8, 5 Hz), 5.21 (2H, s), 5.78, d, J = 6 Hz), 6.99 (1H, br. s), 7.17 (8H, m), 7.35 (2H, m), 7.41 (2H, m), 7.50 (3H, m), 7.64 (1H, d, J = 8.5 Hz), 7.72 (1H, d, J = 9 Hz), 7.91 (1H, d, J = 8 Hz), 8.88 (1H, s), 10.67 (1H, s).


40

Example 45

Preparation of N'-[3S-Hydroxy-4-(N-hydroxyamino)-2R-(2-naphthylmethyl)succinyl]-S-tyrosinylamide.

5

a) N'-[2R-(2,2-Dimethyl-4-oxo-1,3-dioxolan-5S-yl)-3-(2-naphthyl)propanoyl]-S-tyrosinylamide.



10


This compound was prepared by the general method described in Example 1(b) using S-tyrosinylamide in place of tert-leucine methylamide.

15

δ_H [(CD₃)₂SO] 1.47(3H,s), 1.50(3H,s), 2.69(1H,ABq,J = 13.8, 8.1 Hz),
 2.82(1H,ABq, J = 13.8, 5.3 Hz), 3.14(2H,m), 4.38(1H,m), 4.49(1H,d, J = 6.2Hz),
 6.60(2H,d, J = 8.5 Hz), 6.96(3H,m), 7.12(1H,s), 7.38-7.55(3H,m), 7.69(1H,s),
 7.79-8.00(4H,m) and 9.16(1H,s). M⁺ 499 (+ve ion electrospray).

20

b) N'-[3S-Hydroxy-4-(N-hydroxyamino)-2R-(2-naphthylmethyl)succinyl]-S-tyrosinylamide.



25

This compound was prepared by the general method described in Example 1(c) using N'-[2R-(2,2-Dimethyl-4-oxo-1,3-dioxolan-5S-yl)-3-(2-naphthyl)propanoyl]-S-tyrosinylamide.

mp 179-180°C. δ_H [(CD₃)₂SO] 2.70-3.00(5H,m), 3.93(1H,m), 4.20(1H,m), 5.85(1H,d, J = 6.4Hz), 6.60(2H,d, J = 8.2Hz), 6.97(3H,m), 7.23(2H,s), 7.43-7.57(3H,m), 7.72-7.92(4H,m), 8.92(1H,s), 9.17(1H,s) and 10.72(1H,s). (M-H)⁻ 450 (-ve ion electrospray).


5

10

Activity Data

Compound	CD23 proteinase inhibition %	Collagenase inhibition IC ₅₀ uM	TNF processing inhibition % at 1uM
Example 1	88 at 1uM	>10	-
Example 2	90 at 2uM	8.6	45
Comparative Example*	96 at 1uM	0.005	76.4±0.9


- 15 *The comparative example was Example 2 of WO 90/05719, the compound of formula:



wherein R is CH₂S-(2-thienyl) and R¹ is methyl.

Claims

1. A compound of formula (I):



5

wherein:

- R is hydroxy, hydrogen, alkyl, alkenyl, alkynyl or aryl;
- R¹ is arylmethyl or heterocyclmethyl;
- R² is alkyl, alkenyl, aryl, cycloalkyl or cycloalkenyl; and
- 10 R³ is hydrogen, alkyl, alkenyl, alkynyl or aryl;
- with the proviso that;
- if R¹ is phenylmethyl or naphthylmethyl, wherein the phenyl or naphthyl group is unsubstituted or substituted by up to five substituents selected from the group consisting of halogen, (C₁₋₆)alkyl, aryl(C₁₋₆)alkyl, (C₁₋₆)alkoxy,
- 15 (C₁₋₆)alkoxy(C₁₋₆)alkyl, halo(C₁₋₆)alkyl, hydroxy, nitro, amino, mono- and di-N-(C₁₋₆)alkylamino, acylamino, acyloxy, carboxy, carboxy salts, carboxy esters, carbamoyl, mono- and di-N-(C₁₋₆)alkylcarbamoyl, (C₁₋₆)alkoxycarbonyl, aryloxycarbonyl, ureido, guanidino, sulphonylamino, aminosulphonyl, (C₁₋₆)alkylthio, (C₁₋₆)alkyl sulphinyl (C₁₋₆)alkylsulphonyl, heterocyclyl,
- 20 heterocyclyl (C₁₋₆)alkyl, and a (C₃₋₅)alkylene chain linking two adjacent ring carbon atoms to form a carbocyclic ring;
- then R is hydroxy.

25

2. A compound according to claim 1, wherein R is hydroxy.

3. A compound according to claim 2, wherein R is hydroxy, R¹ is 1- or 2-naphthylmethyl; and/or R² is benzyl or t-butyl; and/or R³ is hydrogen or methyl.


4. A compound according to claim 2, wherein R is hydroxy, R¹ is optionally substituted benzyl; R² is t-butyl; and R³ is hydrogen or methyl.

5. A compound according to claim 2, wherein each of R to R³ is selected 5 from the group consisting of the values ascribed to it in the Examples hereinabove.

6. A compound according to claim 2, selected from the group consisting of the compounds described in the Examples hereinabove.

10

7. A compound according to claim 1 or 2, which is a compound of formula (IA):



15


(1A)

8. The use of a compound according to any one of the preceding claims for the production of a medicament for the treatment or prophylaxis of disorders such as allergy, inflammatory disorders and autoimmune disease in which the 20 overproduction of s-CD23 is implicated.


9. A method for the treatment or prophylaxis of disorders such as allergy, inflammatory disorders and autoimmune disease in which the overproduction of s-CD23 is implicated, which method comprises the administration of a compound 25 according to any one of claims 1 to 7 to a human or non-human mammal in need thereof.

10. A pharmaceutical composition for the treatment or prophylaxis of disorders such as allergy, inflammatory disorders and autoimmune disease in 30 which the overproduction of s-CD23 is implicated which comprises a compound

according to any one of claims 1 to 7 and optionally a pharmaceutically acceptable carrier therefor.


11. The use of a compound according to any one of claims 1 to 7 for the production of a medicament for the treatment or prophylaxis of conditions mediated by TNF, including, but not limited to, inflammation, fever, cardiovascular effects, haemorrhage, coagulation and acute phase response, cachexia and anorexia, acute infections, shock states, graft versus host reactions and autoimmune disease.
- 10 12. A method for the treatment or prophylaxis of conditions mediated by TNF, which method comprises the administration of a compound according to any one of claims 1 to 7 to a human or non-human mammal in need thereof.
- 15 13. A method for the treatment or prophylaxis of disorders such as allergy, inflammatory disorders and autoimmune disease in which the overproduction of s-CD23 is implicated, which method comprises the administration to a human or non-human mammal in need thereof of a compound which is an inhibitor of the processing of TNF, with the proviso that the compound is not an inhibitor of a 20 matrix metalloprotease.
14. A process for preparing a compound according to any one of claims 1 to 7, which process comprises:
- (a) deprotecting a compound of formula (II):
- 25
- 

(II)
- wherein R to R³ are as defined hereinabove, and X is a protecting group such as benzyl or trimethylsilyl or
- 30 (b) reacting a compound of formula (III):



(III)

- wherein R to R³ are as defined hereinabove, and any hydroxy group is optionally
 5 protected, with hydroxylamine or a salt thereof, or
 (c) reacting a compound of formula (IV):



(IV)


- 10 wherein R¹ to R³ are as defined hereinabove, with a thiol to give a compound of
 formula (I) wherein R is methyl substituted by alkylthio, arylthio, aralkylthio, or
 heterocyclithio, or
 (d) converting a compound of formula (I) to a different compound of
 formula (I) as defined hereinabove.

15

15. A compound of formula (II) as defined in claim 14 wherein R is hydroxy
 or protected hydroxy.

16. A compound of formula (IV) as defined in claim 14, wherein R¹ is
 20 heterocyclimethyl.

17. A process for preparing a compound according to claim 2, which process
 comprises reacting a compound of formula (X):



25

(X)

wherein R¹ to R³ are as defined hereinabove, and R⁴ and R⁵ are the same or different and each is hydrogen or a hydroxy protecting group, or R⁴ and R⁵ together form a divalent hydroxy protecting group, with hydroxylamine or a salt thereof.

INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP 97/02433

A. CLASSIFICATION OF SUBJECT MATTER
IPC 6 C07C259/06

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 6 C07C C07K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	WO 96 02240 A (SMITHKLINE BEECHAM PLC ;CHRISTIE GARY (GB); WESTON BEVERLEY JANE () 1 February 1996 see page 7 ---	1-17
Y	GB 2 268 934 A (BRITISH BIO TECHNOLOGY) 26 January 1994 see claim 1; examples 1-10 ---	1-17
Y	WO 95 19956 A (BRITISH BIOTECH PHARM ;BECKETT RAYMOND PAUL (GB); WHITTAKER MARK () 27 July 1995 see claim 1; examples 4,16 -----	1-17



Further documents are listed in the continuation of box C.



Patent family members are listed in annex.

* Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- "&" document member of the same patent family

Date of the actual completion of the international search 24 July 1997	Date of mailing of the international search report 13.08.97
Name and mailing address of the ISA European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl, Fax (+31-70) 340-3016	Authorized officer Deffner, C-A

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/EP 97/02433

Patent document cited in search report	Publication date	Patent family member(s)		Publication date
WO 9602240 A	01-02-96	EP 0769939 A		02-05-97

GB 2268934 A	26-01-94	AT 151414 T		15-04-97
		AU 4715293 A		14-02-94
		AU 661410 B		20-07-95
		AU 4715393 A		14-02-94
		CA 2140626 A		03-02-94
		CZ 9500157 A		18-10-95
		DE 4393452 T		01-06-95
		DE 69309686 D		15-05-97
		DE 69309686 T		24-07-97
		EP 0651738 A		10-05-95
		EP 0651739 A		10-05-95
		EP 0754688 A		22-01-97
		FI 950262 A		20-01-95
		WO 9402446 A		03-02-94
		WO 9402447 A		03-02-94
		GB 2268933 A,B		26-01-94
		GB 2287023 A,B		06-09-95
		HK 149396 A		16-08-96
		HU 9500187 A		28-11-95
		HU 70552 A		30-10-95
		JP 7509459 T		19-10-95
		JP 7509460 T		19-10-95
		NO 950226 A		20-01-95
		NZ 254862 A		27-02-96
		PL 307171 A		15-05-95
		SK 7895 A		11-07-95
		US 5643964 A		01-07-97
		ZA 9305351 A		14-02-94
		ZA 9305352 A		16-05-94

WO 9519956 A	27-07-95	AU 1459795 A		08-08-95
		CA 2181570 A		27-07-95
		CN 1138851 A		25-12-96
		DE 19581347 T		05-12-96
		EP 0740652 A		06-11-96
		FI 962904 A		19-07-96
		GB 2299334 A		02-10-96
		HU 75059 A		28-03-97

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/EP 97/02433

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9519956 A		NO 963030 A NZ 278627 A PL 315745 A SK 94196 A ZA 9500480 A	19-09-96 24-04-97 25-11-96 05-03-97 07-02-96